Intradermal Medication Administration

Key Points

• Intradermal injections deliver small medication volumes into the dermis for testing and selected medications.
• Limited dermal blood flow produces slower absorption and minimal systemic exposure for most ID indications.
• Typical ID injection volume is small (often about 0.1 mL for TB/allergy testing); larger therapeutic ID doses are limited by policy because excess volume increases leakage and interpretation error risk.
• Correct technique uses a shallow insertion angle (commonly about 5-15 degrees) with small-gauge needle selection.
• Formation of a wheal/bleb indicates appropriate intradermal placement.
• Common ID uses include tuberculosis testing, allergy testing, local anesthetic testing/administration, selected lesion-directed steroid injections, and some botulinum toxin protocols.
• For Mantoux TST, interpretation is based on induration (not erythema), measured in millimeters within the required read window.
• ID technique uses bevel-up shallow insertion, does not require aspiration, and avoids post-injection massage to prevent spread into deeper tissue.

Equipment

• Ordered intradermal medication and syringe
• Needle typically 25 to 27 gauge and 3/8 to 5/8 in (9.5 to 15.9 mm)
• Antiseptic solution, gauze, and optional adhesive dressing
• Documentation tool for route, site, dose, and response

Procedure Steps

1. Verify patient identity, order, and medication rights before preparation, including that ordered ID volume is within route limit (typically ⇐ 0.5 mL).
2. Select an appropriate site (for example inner/anterior forearm, posterior upper arm, upper back under scapula, or upper chest) according to test/medication protocol.
3. Assess skin integrity and prior adverse intradermal reaction history; avoid sites with lesions, rash, moles, scars, sores, or prominent veins. For intralesional steroids, avoid active infection sites and known steroid-allergy contexts.
4. If skin is visibly soiled, cleanse with soap and water first; then cleanse with alcohol swab in a center-out circular motion (about 2 in/5 cm radius) for about 30 seconds and allow to dry.
5. Insert needle bevel-up at a shallow angle (commonly about 5-15 degrees), advancing only enough to cover the bevel (commonly no more than about 1/8 in) into the dermis.
6. Inject medication slowly to minimize tissue trauma and leakage; routine aspiration is not required for ID technique. Illustration reference: OpenStax Pharmacology Ch.2.3.
7. Confirm wheal/bleb formation, indicating correct placement.
8. For multi-allergen testing, label or map each site clearly to preserve correct allergen-result interpretation.
9. Withdraw needle at the same angle as insertion, engage safety device without recapping when available, and avoid massaging or occlusive covering of skin-test sites; use gentle gauze only if minor bleeding is present.
10. Monitor site for localized redness/wheal and systemic reactions (for example generalized rash, respiratory symptoms, or anaphylaxis) according to protocol.
11. Ensure immediate access to emergency allergy-response medications/equipment when performing allergen testing.
12. For tuberculin skin testing, schedule/perform read at 48-72 hours and repeat testing per policy if the read window is missed.
13. For TST interpretation, assess and measure induration diameter in millimeters (not erythema) and record 0 mm when no induration is present.
14. Do not massage the site after injection.
15. Teach patient to avoid scratching or rubbing the site.
16. Document medication, dose, route, site mapping when applicable, TB measurement details when applicable, and patient response.

Common Errors

• Incorrect injection angle or depth → failed intradermal placement and invalid test result.
• Not confirming wheal/bleb → uncertain medication deposition.
• Rubbing/scratching the site → irritation and inaccurate skin-test interpretation.
• Missing site labeling during multi-allergen testing → interpretation and treatment errors.
• Performing allergy testing without emergency-response readiness → delayed treatment of severe reactions.
• Reading TST by redness instead of induration or outside the read window → invalid TB-screen interpretation risk.
• Massaging site after ID injection → unintended spread into subcutaneous tissue and distorted response.
• Incomplete documentation → unsafe continuity and interpretation gaps.

Related

• oral-medication-administration-safety - Route-specific safety checks align with shared medication-rights workflow.
• medication-rights-and-three-checkpoint-verification - Comprehensive framework for nursing assessment, documentation, and evaluation responsibilities.